阿帕替尼联合消岩汤治疗晚期非鳞非小细胞肺癌临床疗效观察

李小江; 姜珊; 郭姗琦; 刘宏根; 贾英杰

doi:10.3969/j.issn.1000-8179.2017.14.609

阿帕替尼联合消岩汤治疗晚期非鳞非小细胞肺癌临床疗效观察

Clinical research on apatinib combined with Xiaoyan decoction for the treatment of non-squamous non-small cell lung cancer

摘要

摘要:
目的研究观察甲磺酸阿帕替尼片联合消岩汤治疗晚期非鳞非小细胞肺癌（non-small cell lung cancer，NSCLC）的临床疗效。
方法选取晚期非鳞NSCLC患者38例，随机分为阿帕替尼治疗组18例（A组），阿帕替尼联合消岩汤加减方治疗组20例（B组），二组治疗期间均未行手术及放、化疗。
结果晚期非鳞NSCLC患者服用阿帕替尼后中位无进展生存期（median progression free survival，mPFS）可达3个月，阿帕替尼联合消岩汤组mPFS、客观缓解率（objective response rate，ORR）及疾病控制率（disease control rate，DCR）较阿帕替尼单药组差异无统计学意义（P>0.05）；在改善临床症状及不良反应方面，阿帕替尼联合消岩汤组均优于阿帕替尼单药组（P < 0.05）。
结论阿帕替尼联合消岩汤加减方治疗晚期非鳞NSCLC可改善患者临床症状，并降低不良反应的发生率。

Abstract:
Objective To determine the effect of apatinib combined with Xiaoyan decoction for the treatment of non-squamous nonsmall cell lung cancer.
Methods Thirty-eight patients with non-squamous non-small cell lung cancer were randomly categorized into apatinib group (group A, 18 cases) and apatinib combined with Xiaoyan decoction group (group B, 20 cases). All patients did not undergo surgical treatment, radiotherapy, or chemotherapy during the study.
Results The median progression free survival (mPFS) of advanced non-squamous non-small cell lung cancer patients reached up to 3 months. The mPFS, objective response rate, and disease control rate of the apatinib combined with Xiaoyan decoction group showed no significant difference and statistical significance (P> 0.05). The apatinib combined with Xiaoyan decoction group was superior to the apatinib group with regard to alleviating clinical symptoms and adverse reactions (P < 0.05).
Conclusion Xiaoyan decoction combined with apatinib can improve the clinical symptoms of patients and reduce the incidence of adverse reactions in the treatment of advanced non-squamous non-small cell lung cancer.

HTML全文

参考文献(12)

施引文献

资源附件(0)